Patient-centricity in rare diseases
Keeping the needs of patients as a guiding principle has been key to Kyowa Kirin’s recent success, says Richard Johnson
Read More
Search Results for: Richard Johnson
NICE to reassess Kyowa Kirin’s Poteligeo
An appeal lodged by the company and various charities has been upheld by an independent appeal panel
Read More
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
Final appraisal document said that clinical trial evidence for Poteligeo is ‘very uncertain’
Read More
It’s a small world
To understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that they are an essential part of the research equation
Read MoreTop-up details and implications for the NHS
The Richards Review of NHS medicines access has permitted top-ups and Health Secretary Alan Johnson announced that he was accepting all 14 recommendations of cancer czar Professor Mike Richards’ report Improving Access To Medicines For NHS Patients (see list below).
Read More- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
- Study finds mechanical changes in tumour tissue offer new insights for cancer research
- Cambridge study finds AI more accurately assesses eye problems compared to doctors
